Use of Formula Fortified With DHA in Infants With Cystic Fibrosis
Public ClinicalTrials.gov record NCT00530244. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
The Effect of Formula Fortified With Docosahexaenoic Acid (DHA) on Infants With Cystic Fibrosis (CF)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The hypothesis of this study is that feeding infants diagnosed with CF via newborn screening a formula enhanced with a specific fish-oil fatty acid known as DHA will improve growth and decrease pancreatic dysfunction (as measured by human fecal elastase-1 in stool) over the first year of life. Briefly, infants diagnosed with CF in the first month of life whose parents chose not to breast feed their babies will be invited to enroll in a study comparing a standard commercial infant formula (Enfamil) with a formula enriched with arachidonic acid (AA) and docosahexaenoic acid (DHA). The study formula has 3 times the amount of DHA available in commercially available formulas. Infants will have monthly tests of stool elastase and blood work at entry, 3, 6, 9 and 12 months of age.
Study identification
- NCT ID
- NCT00530244
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 76 participants
Conditions and interventions
Conditions
Interventions
- Docosahexaenoic acid (DHA) Dietary Supplement
- Standard formula (Enfamil) Dietary Supplement
Dietary Supplement
Eligibility (public fields only)
- Age range
- Up to 56 Days
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2003
- Primary completion
- Sep 30, 2011
- Completion
- Sep 30, 2011
- Last update posted
- Mar 6, 2018
2003 – 2011
United States locations
- U.S. sites
- 24
- U.S. states
- 12
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UAB/CHS Cystic Fibrosis Center | Birmingham | Alabama | 35233 | — |
| Emory Cystic Fibrosis Center | Atlanta | Georgia | 30322 | — |
| Blank Children's Hospital | Des Moines | Iowa | 50309 | — |
| Cystic Fibrosis Care & Teaching Center | Wichita | Kansas | 67218 | — |
| Kosair Charities | Louisville | Kentucky | 40202 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Children's Hospital | Boston | Massachusetts | 02115 | — |
| Baystate Medical Center | Springfield | Massachusetts | 01199 | — |
| UMass Memorial Healthcare | Worcester | Massachusetts | 01655 | — |
| Children's Mercy Hospital | Kansas City | Missouri | 64108 | — |
| Monmouth Medical Center | Long Branch | New Jersey | 07740 | — |
| The Respiratory Center for Children | Morristown | New Jersey | 07962-1956 | — |
| Albany Medical Center | Albany | New York | 12208 | — |
| Children's Hospital | Buffalo | New York | 14222 | — |
| Schneider Children's Hospital | New Hyde Park | New York | 11040 | — |
| Strong Memorial Hospital | Rochester | New York | 14642 | — |
| Univesity Medical Center | Stony Brook | New York | 11794 | — |
| SUNY Upstate Medical Center | Syracuse | New York | 13210 | — |
| Children's Hospital at Westchester Medical Center | Valhalla | New York | 10595 | — |
| Lewis H Walker CF Pulmonary Center | Akron | Ohio | 44308 | — |
| Lewis H Walker Cystic Fibrosis Center Division of Pulmonary | Akron | Ohio | 44308 | — |
| St. Christopher's Hospital for Children | Philadelphia | Pennsylvania | 19134 | — |
| Children's Hospital of Pittsburgh | Pittsburgh | Pennsylvania | 15231 | — |
| Mountain State University | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00530244, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 6, 2018 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00530244 live on ClinicalTrials.gov.